Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

2.

Basal stem-like cells identified as origin of small cell lung cancer in lab models

3.

From Pathology to Precision: The Story of Leukemia Therapy

4.

Which women need more than mammograms for breast cancer screening?

5.

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot